MGO One Seven LLC Raises Stock Holdings in Amgen Inc. $AMGN

Posted by Donald Scott on Jan 14th, 2026

MGO One Seven LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,553 shares of the medical research company’s stock after acquiring an additional 1,637 shares during the period. MGO One Seven LLC’s holdings in Amgen were worth $2,978,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Laurel Wealth Advisors LLC increased its stake in Amgen by 27,765.8% in the second quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the period. Norges Bank acquired a new position in Amgen in the 2nd quarter valued at about $1,663,726,000. Vanguard Group Inc. raised its stake in Amgen by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 53,711,570 shares of the medical research company’s stock valued at $14,996,807,000 after acquiring an additional 841,117 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after acquiring an additional 687,735 shares during the last quarter. Finally, WoodTrust Financial Corp lifted its position in Amgen by 8,223.6% during the 2nd quarter. WoodTrust Financial Corp now owns 595,634 shares of the medical research company’s stock worth $166,307,000 after acquiring an additional 588,478 shares during the period. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $324.30 on Wednesday. The firm has a market capitalization of $174.63 billion, a price-to-earnings ratio of 25.06, a price-to-earnings-growth ratio of 2.97 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The business’s 50 day simple moving average is $330.88 and its 200-day simple moving average is $305.32. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $346.38.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period last year, the business posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s payout ratio is 73.57%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a research note on Tuesday, November 25th. Guggenheim boosted their price objective on shares of Amgen from $288.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Cantor Fitzgerald raised their target price on shares of Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Erste Group Bank upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Finally, UBS Group raised shares of Amgen to a “strong-buy” rating in a report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $338.55.

View Our Latest Stock Report on AMGN

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own 0.69% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

Positive Sentiment: Multiple sell‑side firms reiterated Buy ratings and bullish outlooks — William Blair kept a Buy, BMO highlighted pipeline momentum, and Goldman Sachs reiterated Buy with a $403 target, all reinforcing upside expectations for AMGN. Amgen: Durable Growth from Core Franchises and High‑Value MariTide Catalysts Support Buy Rating
Positive Sentiment: Goldman Sachs cites strong portfolio execution and six growth drivers, keeping a high price target that suggests meaningful upside from current levels if execution continues. Amgen Growth Story Isn’t Tapped Out Yet, Says Goldman
Positive Sentiment: Amgen reported extension and mid‑stage diabetes data for MariTide showing patients maintained weight loss and saw improved glycemic control — data that bolsters MariTide as a high‑value potential obesity/diabetes franchise. Amgen says MariTide helped trial patients maintain weight loss
Neutral Sentiment: Amgen presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for longer‑term visibility on pipeline and strategy but not an immediate earnings surprise. Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral Sentiment: Ro (telehealth) launched a research collaboration with Amgen to study barriers to obesity care and GLP‑1 access — this could help real‑world adoption and payer conversations over time but has no immediate revenue impact. Ro partners with Amgen to study barriers to obesity care, GLP-1 access
Neutral Sentiment: Coverage pieces from Zacks highlight investor attention and potential earnings surprises in the sector — signals that AMGN is on screens but not a direct catalyst. These 2 Medical Stocks Could Beat Earnings
Negative Sentiment: Despite the MariTide readouts, the stock fell as some investors said the data failed to excite — indicating a gap between expectations and what was disclosed, and suggesting near‑term volatility until larger confirmatory data or clearer commercial signals arrive. Amgen Stock (AMGN) Falls despite Obesity Drug Update — Here’s Wall Street’s Take

About Amgen

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.